Latest Ratios: P/E Ratio -2.8x · EV/EBITDA N/A · ROE -39.3%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $19M | $4M | $1M | $1M | $4M | $10M | $13M | $11M | — | — |
| Enterprise Value | $16M | $855747 | $-2073721 | $-6452100 | $-9309172 | $-44342760 | $5M | $-13035938 | — | — |
| P/E Ratio → | -2.81 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 9.92 | 1.97 | 0.58 | — | 13.71 | 2.90 | 5.79 | 2.36 | — | — |
| P/B Ratio | 1.57 | 0.45 | 0.13 | 0.10 | 0.39 | 0.20 | 0.22 | 0.11 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.41 | -1.04 | — | -31.34 | -13.36 | 2.02 | -2.89 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | — | -1778.5% | 100.0% | -2357.1% | -2010.9% | — | — |
| Operating Margin | -239.8% | -239.8% | -181.4% | — | -6242.4% | -1662.5% | -3539.4% | -2774.3% | — | — |
| Net Profit Margin | -170.1% | -170.1% | -152.8% | — | -14841.1% | -1555.6% | -3388.6% | -2729.3% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.3% | -39.3% | -30.4% | -48.4% | -150.2% | -95.9% | -99.0% | -281.9% | — | — |
| ROA | -36.1% | -36.1% | -26.6% | -33.5% | -113.9% | -59.1% | -51.5% | -126.9% | -1790.9% | -1717.0% |
| ROIC | -65.1% | -65.1% | -58.3% | -2468.4% | — | -183.5% | -97.6% | -294.9% | — | — |
| ROCE | -55.5% | -55.5% | -36.0% | -119.1% | -63.2% | -75.3% | -61.0% | -158.5% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.77 | 0.76 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.36 | -0.37 | -0.67 | -1.28 | -1.12 | -0.15 | -0.24 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -3394.63 | — | — | — | — |
Net cash position: cash ($3M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.15 | 5.15 | 5.83 | 3.85 | 1.94 | 5.00 | 3.45 | 5.55 | 0.05 | 0.09 |
| Quick Ratio | 5.15 | 5.15 | 5.83 | 3.85 | 1.94 | 4.92 | 3.45 | 5.55 | 0.05 | 0.09 |
| Cash Ratio | 3.60 | 3.60 | 4.46 | 3.63 | 1.75 | 4.87 | 3.21 | 5.35 | — | — |
| Asset Turnover | — | 0.21 | 0.21 | — | 0.02 | 0.06 | 0.02 | 0.02 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 175.99 | 101.47 | — | 117.98 | 10.99 | 20.19 | 119.37 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.7% | 3.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.7% | 3.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $460714 | $359714 | $334000 | $310429 | $279600 | $217164 | $195571 | $195032 | $195029 |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KRSA stock.
Korsana Biosciences, Inc.'s current P/E ratio is -2.8x. This places it at the 50th percentile of its historical range.
Korsana Biosciences, Inc.'s return on equity (ROE) is -39.3%. The historical average is -106.4%.
Based on historical data, Korsana Biosciences, Inc. is trading at a P/E of -2.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Korsana Biosciences, Inc. has 100.0% gross margin and -239.8% operating margin.
Key Metrics
Top Statement Risk
Imminent liquidity and insolvency
Metrics are mathematically derived from official filings.
Distressed Valuation Reflects Liquidity Crisis
According to recent market data, Cyclerion trades at a P/S ratio of 7.06, a multiple that appears disconnected from the company's lack of recurring revenue and suggests that investors are pricing the stock as a distressed option rather than a viable, long-term clinical-stage biotechnology entity.
The current P/B ratio of 1.20 indicates that the market is assigning minimal value to the company's intellectual property beyond its liquidation value. This valuation suggests that the market has largely discounted the potential of the sGC platform, viewing the firm's survival as the primary variable rather than the long-term commercial success of its pipeline.
Capital Decay Undermines Platform Value
Based on reported financial figures, the company's ROIC has consistently trended into deep negative territory, reaching -49.1% in 2026Q1, which highlights a severe inability to generate returns on invested capital while the firm continues to consume resources to fund its specialized CNS-penetrant research initiatives.
The persistent negative ROIC trend suggests that the capital allocated to R&D is not currently translating into tangible value creation for shareholders. Investors should monitor whether the company can pivot to a more efficient capital allocation model, as the current trajectory indicates a rapid erosion of the firm's intrinsic value.
Working Capital Volatility Masks Inefficiency
As reported in recent financial statements, the company's asset turnover ratio has remained negligible, fluctuating near 0.10, which underscores the lack of operational scale and the firm's reliance on non-recurring milestone payments rather than a sustainable, high-velocity commercial engine to drive its working capital cycle.
The extreme volatility in DSO, which spiked to 541 in 2025Q2, suggests that the company's collection cycle is highly irregular and dependent on the timing of specific licensing agreements. This lack of operational consistency makes traditional efficiency metrics less meaningful and highlights the firm's structural dependence on external funding.
Liquidity Buffer Nearing Critical Depletion
According to the 2026Q1 balance sheet, the company's current ratio of 1.80 provides a misleading sense of security, as the absolute cash balance of $3.24 million is insufficient to cover the high fixed costs of clinical trial execution, leaving the firm in a highly vulnerable position.
The rapid decline in liquidity suggests that the company may face an imminent need for dilutive financing or a strategic asset sale to maintain operations. The lack of a clear path to self-funding indicates that the current liquidity position is likely to deteriorate further without a significant change in the firm's capital structure.
Misapplied Metrics Obscure Burn Reality
Analysts frequently misapply the P/S ratio to Cyclerion, which obscures the reality that the company's revenue is transactional and non-recurring, failing to account for the massive R&D burn that is the true driver of the firm's financial health and long-term viability as a going concern.
Instead of relying on revenue-based multiples, investors should focus on the 'Cash Runway to Data' metric, which better captures the firm's survival risk. Using P/S in a pre-commercial biotech context ignores the fundamental reality that the company is currently a cash-burning research entity rather than a revenue-generating business.